Phase II study of cryoablation and post-progression immune checkpoint inhibition in metastatic melanoma
收藏NIAID Data Ecosystem2026-05-02 收录
官方服务：
资源简介：
To be updated
应用场景：
创建时间：
2024-08-09
相关数据集
Real-world data on PD-1 inhibitor therapy in metastatic melanoma
Introduction: Phase III studies of PD-1 inhibitors have demonstrated remarkable improvements in the survival of patients with metastatic melanoma (MM). If these results are generalizable to an
DataCite Commons2020-08-27 更新80
A TCR/anti-CD3 bispecific fusion protein targeting gp100 potently activated anti-tumor immune responses in metastatic melanoma. A TCR/anti-CD3 bispecific fusion protein targeting gp100 potently activated anti-tumor immune responses in metastatic melanoma
Tumor-specific cytotoxic T cells are required for effective immunotherapy. Here we introduce a bispecific fusion protein (tebentafusp) designed to target gp100 (a melanoma-associated antigen) through
NIAID Data Ecosystem30
POG_patient_32572 - samples
Genome and transcriptome sequence data from a metastatic melanoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) studyEGA dataset EGAD00001003735
NIAID Data Ecosystem20
Table_4_Cryoablation reshapes the immune microenvironment in the distal tumor and enhances the anti-tumor immunity.xlsx
As one of the local treatments, cryoablation plays an increasingly important role in the comprehensive treatment of malignant tumors with its advantages of less trauma, high reproducibility, and minim
NIAID Data Ecosystem30
Understanding heterogeneous tumor microenvironment in metastatic melanoma
A systemic analysis of the tumor-immune interactions within the heterogeneous tumor microenvironment is of particular importance for understanding the antitumor immune response. We used multiplexed im
NIAID Data Ecosystem30
